SummaryRMgm-4542
|
Successful modification | The parasite was generated by the genetic modification |
The mutant contains the following genetic modification(s) | Gene mutation, Introduction of a transgene |
Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 30307699 |
MR4 number | |
top of page | |
Parent parasite used to introduce the genetic modification | |
Rodent Malaria Parasite | P. berghei |
Parent strain/line | P. berghei ANKA |
Name parent line/clone | P. berghei ANKA 507cl1 (RMgm-7) |
Other information parent line | |
top of page | |
The mutant parasite was generated by | |
Name PI/Researcher | Ishino T, Torii M |
Name Group/Department | Division of Molecular Parasitology |
Name Institute | Proteo-Science Center, Ehime University |
City | Toon, Ehime |
Country | Japan |
top of page | |
Name of the mutant parasite | |
RMgm number | RMgm-4542 |
Principal name | P(msp9)-RON2 |
Alternative name | |
Standardized name | |
Is the mutant parasite cloned after genetic modification | Yes |
top of page | |
Phenotype | |
Asexual blood stage | Not different from wild type |
Gametocyte/Gamete | Not different from wild type |
Fertilization and ookinete | Not different from wild type |
Oocyst | Not different from wild type |
Sporozoite | Mutant sporozoites developed and matured normally in oocysts. ron2 mRNA levels in mutant sporozoites were approximately 50-fold less, compared to wild-type sporozoites and RON2 protein amount is decreased approximately 50-fold. Mutant (hemolymph) sporozoites were strongly reduced (20-fold reduction) in invading salivary glands. Reduced motility of mutant sporozoites. Mutant sporozoites showed reduced capacity to invade hepatocytes (and reduced infectivity to mice). |
Liver stage | Mutant (hemolymph) sporozoites were strongly reduced (20-fold reduction) in invading salivary glands. Reduced motility of mutant sporozoites. Mutant sporozoites showed reduced capacity to invade hepatocytes (and reduced infectivity to mice). |
Additional remarks phenotype | Mutant/mutation In the paper two other 'promoter-swap' mutants are described where the ron2 promoter regions has been replaced with promoter regions of rap1 (PBANKA_1032100) and msp1 (BANKA_0831000) |
top of page | |||||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||||
Gene Model of Rodent Parasite | PBANKA_1315700 | ||||||||||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_1452000 | ||||||||||||||||||||||||||
Gene product | rhoptry neck protein 2 | ||||||||||||||||||||||||||
Gene product: Alternative name | RON2 | ||||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||||
Short description of the mutation | 'promoter-swap' mutant; the promoter of RON2 replaced by the promoter of PBANKA_1443300 (msp9) | ||||||||||||||||||||||||||
Inducable system used | No | ||||||||||||||||||||||||||
Short description of the conditional mutagenesis | Not available | ||||||||||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||||||||||
Type of plasmid/construct | (Linear) plasmid double cross-over | ||||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | hdhfr | ||||||||||||||||||||||||||
Promoter of the selectable marker | eef1a | ||||||||||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||||||||||
Additional remarks genetic modification | To generate sporozoite stage-specific ron2 silencing transgenic parasites, the 5′UTR region of ron2 was replaced with a merozoite-specific candidate promoter region by double crossover homologous recombination within the GFP background strain. Two homologous recombination cassettes, ron2 upstream (-1683 to -845 bp relative to RON2 start of translation) and RON2-N (-105 to +945 bp) respectively, were sub-cloned into a transgenic vector containing a human DHFR expression cassette (hDHFR) used for drug selection. The promoter region of msp9 (PBANKA_1443300) was also sub-cloned into the transgenic vector immediately before the RON2-N region. | ||||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||||
| |||||||||||||||||||||||||||
top of page |
top of page | |||||||||||||||||||
Type and details of transgene | |||||||||||||||||||
Is the transgene Plasmodium derived | Transgene: not Plasmodium | ||||||||||||||||||
Transgene name | GFP (gfp-mu3) | ||||||||||||||||||
top of page | |||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||
Inducable system used | No | ||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||
Type of plasmid/construct | (Linear) plasmid double cross-over | ||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||
Selectable marker used to select the mutant parasite | gfp (FACS) | ||||||||||||||||||
Promoter of the selectable marker | eef1a | ||||||||||||||||||
Selection (positive) procedure | FACS (flowsorting) | ||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||
Additional remarks genetic modification | The GFP gene (1 copy) has been inserted into the 230p locus (PBANKA_030600) by double cross-over integration. | ||||||||||||||||||
Additional remarks selection procedure | This reporter mutant expressing GFP does not contain a drug-selectable marker. This mutant has been selected by FACS sorting after transfection based on GFP fluorescence. | ||||||||||||||||||
top of page | |||||||||||||||||||
Other details transgene | |||||||||||||||||||
top of page | |||||||||||||||||||
Promoter | |||||||||||||||||||
Gene Model of Parasite | PBANKA_1133300 | ||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_1357100 | ||||||||||||||||||
Gene product | elongation factor 1-alpha | ||||||||||||||||||
Gene product: Alternative name | eef1a | ||||||||||||||||||
| |||||||||||||||||||
top of page | |||||||||||||||||||
3'-UTR | |||||||||||||||||||
Gene Model of Parasite | PBANKA_0719300 | ||||||||||||||||||
Gene product | bifunctional dihydrofolate reductase-thymidylate synthase, putative | ||||||||||||||||||
Gene product: Alternative name | dhfr/ts | ||||||||||||||||||
| |||||||||||||||||||
Insertion/Replacement locus | |||||||||||||||||||
Replacement / Insertion | Replacement locus | ||||||||||||||||||
Gene Model of Parasite | PBANKA_0306000 | ||||||||||||||||||
Gene product | 6-cysteine protein | ||||||||||||||||||
Gene product: Alternative name | 230p | ||||||||||||||||||
| |||||||||||||||||||
top of page |